The importance of stable cell lines cannot be overstated in laboratory research and the pharmaceutical industry. These cell lines are instrumental in various applications, such as studying gene function, assessing toxicity levels, producing recombinant proteins and antibodies, conducting drug screening, and investigating potential cancer therapies.

Their stability and reliability make them indispensable tools in advancing scientific knowledge and developing innovative treatments.

In clinical applications, two commonly used cell line types are monoclonal and polyclonal. Monoclonal cell lines are derived from a single parent cell or progenitor, ensuring genetic homogeneity. However, the risks associated with polyclonal cell lines (multicellular in origin), such as instability and variability, limit their applications. Therefore, monoclonal cell lines are more prominent in therapeutic applications.

Establishing the monoclonal nature of cell lines is crucial to produce biopharmaceutical products, such as antibodies, to ensure consistent product quality, drug efficacy and patient safety.

The process of assuring the quality of the produced cell lines by manufacturers or ensuring their single cell origin is known as monoclonality assurance. Traditionally, single cell clones were isolated and diluted to determine their monoclonal nature. However, on a commercial scale, it was a labor-intensive process.

This article covers more about methods to obtain single cell clones, including the techniques for monoclonal verifications, regulatory considerations, importance, difficulties, and potential solutions.

Methods to Obtain Single Cell Clones

A mix of traditional and advanced approaches is available today to ensure the monoclonality of a cell line. Some of them are mentioned below:

• Limiting dilution cloning: It's a practical and cost-effective method for achieving monoclonality of cell lines by leveraging the principles of the Poisson distribution. This technique involves the efficient isolation of individual cells from diluted cell suspensions using either manual or automated pipettes. However, several limitations are associated with the process, including:

  • High occurrence of multiple cells in a well.
  • High occurrence of no cells in a well.
  • Low cell survival rates.
  • Identifying clones from single cells is challenging with a standard microscope.
  • The process requires repetition and large volumes of plastic multi-well plates to obtain a monoclonal cell cluster.
  • Monoclonality is not guaranteed.

• Colony formation assays: Clonogenic assays assess the capability of a single cell to multiply and form a colony (defined as a group of at least 50 cells).

• Single cell cloning: It's an essential step in creating monoclonal cell lines during the cell line development (CLD) process for biopharmaceuticals. These cell lines are instrumental in producing recombinant proteins, monoclonal antibodies, and viral vectors for vaccines and gene therapies.

• FACS (Fluorescence-Activated Cell Sorting): It is a widely employed method that focuses on isolating specific live cells of interest. Through this technique, cells are meticulously concentrated into a slender flow of sheath fluid and sorted based on phenotypic characteristics like surface markers or transgene expression.

Monoclonality Validation & Authentication

After obtaining single cell clones, it is important to validate if your cell line is in fact monoclonal in nature. The most widely used method is genetic sequencing (whole genome sequencing). This process probes genetic homogeneity of clones to ensure identity and conservation of important genetic traits from one generation to the next. The profiling of Short Tandem Repeat (STR) genomic regions through PCR-based methods is another method to authenticate your monoclonal cell line.

Functional assays can characterize the monoclonal cell line’s ability to maintain desired functional cellular attributes. One example would be testing the differentiation potential of a monoclonal stem cell line.

Monoclonal assurance is important for regulatory reporting purposes. It provides evidence of the identity and genetic stability of your cell line. The testing also documents purity to show there is no cross-species contamination (e.g., mycoplasma).

Regulatory Considerations

In the United States, the development, manufacturing, and use of antibodies as therapeutics falls under the regulatory purview of the FDA, specifically the Center for Biologics Evaluation and Research (CBER) and Drug Evaluation and Research.

To guide manufacturers in the development and testing of monoclonal antibodies (mAbs) for human use, the FDA has issued a comprehensive document known as "Points to Consider." This guidance emphasizes the importance of purity in immunoconjugates and the efficacy of purification methods in eliminating potential contaminants.

Stringent regulations aim to prevent human pathogen contamination in the final product, necessitating measures to maintain cell culture integrity and animal care standards. Commercial production of recombinant proteins mandates that cell lines originate from a single cell progenitor or clone, which ensures the highest level of quality and consistency in the drug product.

By demonstrating a high level of monoclonality in production cell lines, companies can meet regulatory standards and ensure the homogeneity of the final biopharmaceutical product. This commitment to monoclonality reduces variability between batches and guarantees consistent composition and efficacy in each therapeutic dose given to patients.

Importance of Monoclonality Assurance in Biopharmaceutical Development

The clonality assurance of a cell bank ensures consistent manufacturing of a product by minimizing the use of heterogeneous cell lines. Without a clonal cell line, undesired cell populations may emerge from changes in manufacturing processes, leading to alterations in the final product. This can adversely affect a patient's health.

Further, it also creates challenges for the manufacturers by delaying product availability in the market. For instance, troubleshooting to address these changes may cause disruptions in product supply. Thus, maintaining a clonal cell line helps to mitigate these risks and ensures the stability and reliability of the manufacturing process.

Challenges and Considerations in Monoclonality Assurance

Validating the single cell origin of cultures is a complex and time-consuming task that significantly influences the success of cell line development. Regulatory filing should include time-series images of cell cultures to ensure their monoclonality and the production of consistent products.

Genetic instability in cell lines over time and the occurrence of heterogeneity are aspects that must be monitored regularly with each cell bank.  Appropriate statistical approaches are required to assess the monoclonality of cell lines and produce accurate and reliable results.

To ensure the monoclonality of the manufactured products and their effects on patients, it’s essential to take the following considerations into account during the manufacturing process:

• Patient sensitivity to certain agents, such as antibiotics, means their use in cell culture or bioreactor systems should be avoided as they can elicit unwanted in vivo reactions.
• Biological reagents, especially serum or serum constituents, must be routinely tested for adventitious agents to show they are free from contamination. A best practice is to avoid the use of serum.
• Stability testing for cell lines is an important aspect to consider. Cell lines may develop genetic anomalies and mutations over prolonged culturing that can lead to undesired product attributes and decreases in productivity.

Best Practices for Monoclonality Assurance

Here are a few suggestions to consider for verifying the monoclonality of your cell lines:

• Implement rigorous screening and characterization methods to identify and select high-producing, stable monoclonal cell lines.
• Perform regular genetic stability assessments to detect any genetic alterations or clonal evolution.
• Implement robust documentation practices to maintain traceability and provide evidence of monoclonality assurance.
• Continuously monitor cell culture conditions to minimize clonal heterogeneity and ensure consistent product quality.
• Follow regulatory guidelines and quality standards, such as those provided by regulatory authorities like the FDA, to ensure compliance and product quality.

recent-articles